CBI-1214
/ Cartography Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
April 21, 2026
A phase 1, first-in-human (FIH), dose-escalation and dose‑optimization study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 T-cell engager in participants with advanced or metastatic microsatellite-stable (MSS)/microsatellite instability–low (MSI‑L) colorectal cancer (CRC).
(ASCO 2026)
- P1 | "After an up-to-28-day screening period, eligible patients receive study medication and are followed for their entire treatment period plus a follow-up period of approximately 90 days. The study is open for recruitment in the United States (NCT07321106)."
Clinical • First-in-human • Metastases • P1 data • PK/PD data • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • LY6G6D • MSI
February 24, 2026
Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer
(Businesswire)
- "The Phase 1, first-in-human, open-label study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CBI-1214, a novel T-cell engager, in adult participants with advanced or metastatic microsatellite stable (MSS) or microsatellite instability-low (MSI-L) colorectal cancer."
First-in-human • Trial status • Colorectal Cancer • Microsatellite Instability
January 07, 2026
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
(clinicaltrials.gov)
- P1 | N=80 | Recruiting | Sponsor: Cartography Biosciences
First-in-human • New P1 trial • Colon Cancer • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI
December 18, 2025
Cartography Receives FDA Investigational New Drug (IND) Approval and Fast Track Designation for Lead Program CBI-1214 for Colorectal Cancer
(PharmiWeb)
- "Cartography anticipates initiating its Phase I clinical trial in the first quarter of 2026."
Fast track • IND • New P1 trial • Colorectal Cancer
1 to 4
Of
4
Go to page
1